Pharmaceuticals, Biotechnology and Life Sciences
FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing…
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual…
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema…
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has…
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data…
Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is…
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of…
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company…
The new African American Genetic Groups feature traces customers’ ancestral connections from before the early-to-mid-20th century migrations to more than…
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a…